Published in Annu Rev Pharmacol Toxicol on January 01, 2010
The economic value of personalized medicine tests: what we know and what we need to know. Genet Med (2013) 1.40
Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther (2013) 1.10
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics (2013) 0.89
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics (2013) 0.88
Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers Med (2015) 0.82
Stratified medicine and reimbursement issues. Front Pharmacol (2012) 0.80
Economic evaluation of personalized medicine: a call for real-world data. Eur J Health Econ (2017) 0.75
Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J (2016) 0.75
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Genomics and drug response. N Engl J Med (2011) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
A high-resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genet (2006) 3.24
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost (2004) 2.64
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A (2004) 2.37
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Returns on research and development for 1990s new drug introductions. Pharmacoeconomics (2002) 2.29
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost (2005) 2.25
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther (2009) 2.10
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs (2005) 2.09
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.95
Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med (2013) 1.89
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther (2006) 1.82
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol (2008) 1.81
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet (2005) 1.75
Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology (2008) 1.68
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol (1985) (2003) 1.55
Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol (2005) 1.52
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
Pharmacogenomic discovery approaches: will the real genes please stand up? J Clin Oncol (2005) 1.49
wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. Nucleic Acids Res (2008) 1.48
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol (2007) 1.46
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer (2003) 1.41
Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502d7 that demethylates codeine to morphine", J Biol Chem 279: 27383-27389. Drug Metab Dispos (2005) 1.38
Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer (2003) 1.36
CANDID: a flexible method for prioritizing candidate genes for complex human traits. Genet Epidemiol (2008) 1.36
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics (2011) 1.34
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics (2008) 1.33
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol (2009) 1.32
Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res (2006) 1.31
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res (2002) 1.31
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Validation of the Confusion Assessment Method for the Intensive Care Unit in older emergency department patients. Acad Emerg Med (2014) 1.29
Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet (2006) 1.28
Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum (2006) 1.27
PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat (2012) 1.23
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics (2012) 1.23
Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci (2009) 1.21
Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer (2007) 1.21
Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) 1.21
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res (2008) 1.20
Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther (2007) 1.18
Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol (2002) 1.17
PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics (2011) 1.16
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res (2004) 1.16
Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta (2003) 1.15
PromoLign: a database for upstream region analysis and SNPs. Hum Mutat (2004) 1.15
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther (2004) 1.13
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn (2009) 1.12
PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Hum Mutat (2005) 1.12
Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics (2004) 1.09
Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet (2005) 1.09
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res (2004) 1.09
Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics (2009) 1.08
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics (2009) 1.07
Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet (2004) 1.07
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics (2008) 1.07
The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci (2006) 1.06
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res (2006) 1.05
Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics (2009) 1.05
SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat (2002) 1.05
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther (2004) 1.04
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother (2010) 1.03
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin Cancer Res (2005) 1.02
Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet (2014) 1.02
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
The candidate oncogene ZNF217 is frequently amplified in colon cancer. J Pathol (2004) 1.01
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics (2009) 1.01
Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics (2005) 1.00
Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother (2007) 1.00
Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003) (2014) 1.00
Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics (2014) 1.00
Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees. PLoS One (2011) 1.00
Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med (2005) 1.00
Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res (2005) 1.00
CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet (2005) 0.99
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res (2008) 0.99
Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. Pharmacogenomics (2008) 0.99
Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines. Mol Cancer Ther (2011) 0.98
Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics (2006) 0.97
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics (2008) 0.97
Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol (2005) 0.96
Multivariate methods and software for association mapping in dose-response genome-wide association studies. BioData Min (2012) 0.96